# Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer

> **NCT02500121** · PHASE2 · COMPLETED · sponsor: **Matthew Galsky** · enrollment: 108 (actual)

## Conditions studied

- Urothelial Carcinoma
- Bladder Cancer

## Interventions

- **OTHER:** Placebo
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02500121
- **Lead sponsor:** Matthew Galsky
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11-11
- **Primary completion:** 2019-07-01
- **Final completion:** 2021-01-01
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2022-09-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02500121

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02500121, "Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02500121. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*